Le Lézard
Classified in: Health, Science and technology
Subject: POL

Convergence Ramps Up Strategy and Investments to Solve Critical National Issues and Lower Toxic Polarization


Bridge-building leader will intensify collaborative problem-solving to strengthen economic opportunity, health and wellness, and democracy and civic engagement

WASHINGTON, Sept. 12, 2022 /PRNewswire/ -- Convergence Center for Policy Resolution, the bridge-building leader in consensus-driven problem-solving, has launched a significant expansion and acceleration of its work to bridge toxic divisions and address intractable issues in America, according to the new 5-Year Strategy Convergence made public today.

"If there was ever an all-hands-on-deck moment for addressing divisiveness and dysfunction in America, this is it."

Citing extensive statistics that document alarm among citizens, national security experts, corporate leaders, and other communities about the level of toxic polarization and problem-solving paralysis, the published 5-Year Strategy offers a blueprint for Convergence to drive greater impact and marshal increased resources in pursuit of twin goals: producing actionable solutions to urgent problems and fostering a culture of collaboration across differences.

"If there was ever an all-hands-on-deck moment for addressing divisiveness and dysfunction in America, this is it," said Convergence CEO David Eisner. "At Convergence, we're doing our part to meet the urgent demands of a dangerously polarized America in three ways. We're doubling-down on our reliably successful bridge-building, consensus-forging and problem-solving to solve more issues and reach more people across communities and sectors; we're leveraging this well-honed approach to address toxic polarization and problem-solving dysfunction more systemically; and we're building new pathways to inspire, equip and mobilize others to help make collaboration a norm across the country."

Key to its new strategy, Convergence is bringing intensified focus to three Impact Areas:

About Convergence Center for Policy Resolution

Convergence is the leading national organization building bridges across differences to address critical issues. For more than a decade, Convergence has facilitated nonpartisan collaborations among leaders divided along political, ideological, sectoral, and identity-based lines to produce solutions that create meaningful change in the lives of millions of Americans. For more information, visit convergencepolicy.org.

Contact: [email protected] 

SOURCE Convergence Center for Policy Resolution


These press releases may also interest you

23 fév 2024
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 8, 2024 to file lead plaintiff applications in a securities class action lawsuit against iRhythm Technologies, Inc. , if they purchased the Company's...

23 fév 2024
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 9, 2024 to file lead plaintiff applications in a securities class action lawsuit against Amylyx Pharmaceuticals, Inc. , if they purchased the Company's...

23 fév 2024
The "North America and Europe Managed Equipment Services (MES) Market, Forecast to 2028" report has been added to  ResearchAndMarkets.com's offering. The study period is 2022-2028, with 2023 as the base year and 2024-2028 as the forecast period. The...

23 fév 2024
Easterseals South Florida (ESSF) is proud to announce that Matthew Roth, President of Solstice Point Partners, LLC has been appointed as Board Chair. "My journey at Easterseals South Florida began with a personal connection and commitment to...

23 fév 2024
The "Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts. Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI Etc.), by Country, with Market Analysis, Executive Guides and Customization" report has been added to...

23 fév 2024
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to...



News published on and distributed by: